Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $17000.0.

  • Cytosorbents' Capital Expenditures fell 8881.58% to $17000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $125343.0, marking a year-over-year decrease of 5963.15%. This contributed to the annual value of $284343.0 for FY2024, which is 4715.94% down from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' Capital Expenditures is $17000.0, which was down 8881.58% from -$213783.0 recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Capital Expenditures registered a high of $3.1 million during Q2 2022, and its lowest value of -$213783.0 during Q2 2025.
  • Over the past 5 years, Cytosorbents' median Capital Expenditures value was $213437.0 (recorded in 2022), while the average stood at $558266.9.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 87408.1% in 2021, then tumbled by 130042.11% in 2025.
  • Over the past 5 years, Cytosorbents' Capital Expenditures (Quarter) stood at $1.5 million in 2021, then tumbled by 86.07% to $213437.0 in 2022, then crashed by 55.26% to $95497.0 in 2023, then decreased by 27.39% to $69343.0 in 2024, then plummeted by 75.48% to $17000.0 in 2025.
  • Its last three reported values are $17000.0 in Q3 2025, -$213783.0 for Q2 2025, and $252783.0 during Q1 2025.